Emerging role of genetic variants of matrix metalloproteinases genes in left ventricular dysfunction

Role of Proteases in Cellular Dysfunction

Volumn , Issue , 2014, Pages 321-334

  Mittal, Balraj ^a   Mishra, Avshesh ^a   Srivastava, Anshika ^a   Garg, Naveen ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Coronary artery disease (CAD); Left ventricle ejection fraction (LVEF); Left ventricular dysfunction; MMP genetic variants

Indexed keywords

EID: 84897936293     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9099-9_17     Document Type: Chapter

References (20)

1. Gibbons GH, Liew CC, Goodarzi MO, et al (2004) Genetic markers: progress and potential for cardiovascular disease. Circulation; 109:IV47-58.
2. Triposkiadis F, Karayannis G, Giamouzis G, et al (2009) The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol; 54:1747-1762.
3. Cassar A, Holmes DR, Rihal CS, et al (2009) Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc; 84:1130-1146.
4. Spinale FG, Coker ML, Thomas CV, et al (1998) Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res; 82:482-495.
5. Peterson JT, Li H, Dillon L, et al (2000) Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res; 46:307-315.
6. Spinale FG, Coker ML, Heung LJ, et al (2000) A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation; 102:1944-1949.
7. Lindsey ML, Gannon J, Aikawa M, et al. (2002) Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation; 105:753-758.
8. Mishra A, Srivastava A, Mittal T, et al (2012) Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients. Clin Chim Acta; 413:1668-1674.
9. Gunja-Smith Z, Morales AR, Romanelli R, et al (1996) Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol; 148:1639-1648.
10. Rohde LE, Ducharme A, Arroyo LH, et al (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation; 99:3063-3070.
11. Schiller NB, Shah PM, Crawford M, et al. (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr; 2:358-367.
12. Mishra A, Srivastava A, Mittal T, et al (2012) Impact of renin-angiotensin-aldosterone system gene polymorphisms on left ventricular dysfunction in coronary artery disease patients. Dis Markers; 32:33-41.
13. Miller SA, Dykes DD, Polesky HF. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res; 16:1215.
14. Singh R, Srivastava P, Srivastava A, et al (2010) Matrix metalloproteinase (MMP-9 and MMP- 2) gene polymorphisms influence allograft survival in renal transplant recipients. Nephrol Dial Transplant; 25:3393-3401.
15. Malik MA, Sharma KL, Zargar SA, et al (2011) Association of matrix metalloproteinase-7 (-181A > G) polymorphism with risk of esophageal squamous cell carcinoma in Kashmir Valley. Saudi J Gastroenterol; 17:301-306.
16. Meigs JB, Shrader P, Sullivan LM, et al. (2008) Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med; 359:2208-2219.
17. Bhave PD, Hoffmayer KS, Armstrong EJ, et al. (2012) Predictors of depressed left ventricular function in patients presenting with ST-elevation myocardial infarction. Am J Cardiol; 109:327-331.
18. Sole X, Guino E, Valls J, Iniesta R, et al (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics; 22:1928-1929.
19. Murphy G, Knauper V (1997) Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol; 15:511-518.
20. O'Farrell TJ, Pourmotabbed T (2000) Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase B. J Biol Chem; 275:27964-27972.